Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Adello’s Filgrastim Biosimilar Faces Infringement Lawsuit And Potential Regulatory Delay

May 29 2018

• By Sue Sutter

Related Content

US Supreme Court Permits Earlier Biosimilar Launches; Penalty For Declining Patent Dance Uncertain

Jun 13 2017

Biosimilar Legal Landscape: Lessons From 2017

Jan 03 2018

US FDA's Biosimilars Program: Five Years In, Complete Response Letters Still Outnumber Approvals

May 29 2018

Zarxio 15% Price Discount To Neupogen In US Tracks European Strategy

Sep 03 2015

Related Companies

Amgen, Inc.

Novartis AG

Apotex Inc.

Pfizer Inc.

Amneal Pharmaceuticals, Inc.

Additional Topics

United States Biosimilars Intellectual Property Legal Issues Regulation Blood & Coagulation Disorders Cancer BioPharmaceutical

More from Biosimilars

More from Biosimilars & Generics

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window